Possible involvement of interleukin-18 in the pathology of hepatobiliary adverse effects related to treatment with ceritinib
Open Access
- 19 October 2018
- journal article
- case report
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 995
Abstract
Ceritinib demonstrated a statistically significant effect on the progression-free survival versus chemotherapy in patients with advanced anaplastic lymphoma kinase (ALK) rearrangement in non-small cell lung cancer (NSCLC) as the first therapy or after previous treatment with crizotinib and one or two prior chemotherapy regimens in global phase 3 studies. However, some serious adverse effects related to ceritinib therapy were reported across these clinical studies. Among them, a grade 3 and 4 increase in hepatobiliary enzymes was one of the common adverse events related to treatment with ceritinib. However, the pathology remains unclear. Previously, increased Interleukin (IL)-18 was observed in both biliary duct disease and liver disease. Therefore, we hypothesized that IL-18 is involved in the pathology of hepatobiliary adverse effects related to treatment with ceritinib and evaluated the serum IL-18. The patient was a 53-year-old Japanese woman that we previously reported as having severe hepatobiliary adverse effects related to ceritinib therapy. Laboratory data, CT and MRI were obtained at each time point. IL-18 was evaluated by ELISA method at each time point. Immunochemical staining of liver tissue was performed as a standard protocol using antibodies against IL-18. Our records showed that the levels of serum IL-18 increased from the early stage of hepatobiliary adverse effects related to the treatment with ceritinib and were became worse with an increase in hepatobiliary enzymes and the progression of imaging abnormalities in the bile duct. Furthermore, IL-18 positive cells were detected in the inflammatory sites around the interlobular bile duct of the liver tissue. Our case report shows that the increase of serum IL-18 had a positive correlation with the progression of severe hepatobiliary adverse effects related to treatment with ceritinib and the involvement of IL-18 in the hepatobiliary inflammation by pathological evaluation. These results suggest that IL-18 could be a useful surrogate marker for the hepatobiliary toxicity of ceritinib. However, this is only one case report and further prospective observations will complement our data in the future.Keywords
Funding Information
- Japan Society for the Promotion of Science (#18K15915)
This publication has 13 references indexed in Scilit:
- First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 studyThe Lancet, 2017
- Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with baseline brain metastases (BM)Annals of Oncology, 2016
- Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2Journal of Clinical Oncology, 2016
- Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trialThe Lancet Oncology, 2016
- OX40 ligand newly expressed on bronchiolar progenitors mediates influenza infection and further exacerbates pneumoniaEMBO Molecular Medicine, 2016
- IL-18 in autoimmunity: review.2006
- Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.2004
- Plasma Levels of Interleukin-18 and Interleukin-18 Binding Protein Are Elevated in Patients with Chronic Liver DiseaseJournal of Clinical Immunology, 2002
- Increased Concentrations of Plasma Interleukin-18 in Patients With Hepatic Failure 1 Week After SurgeryJournal of Immunotherapy, 2002
- Serum interferon-gamma-inducing factor/IL-18 levels in primary biliary cirrhosisClinical and Experimental Immunology, 2000